冠昊生物(300238) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥128,441,392.59, representing a 37.59% increase compared to ¥93,348,010.41 in the same period last year[8]. - Net profit attributable to shareholders was ¥18,247,093.30, up 57.99% from ¥11,549,674.96 year-on-year[8]. - The net profit after deducting non-recurring gains and losses was ¥16,117,136.00, an increase of 83.58% compared to ¥8,779,539.66 in the previous year[8]. - Basic earnings per share increased to ¥0.07, a 75.00% rise from ¥0.04 in the previous year[8]. - The company reported a total comprehensive income of ¥16,544,859.18 for Q1 2021, compared to ¥11,701,532.94 in the previous year, representing an increase of approximately 41.5%[48]. - The net profit for Q1 2021 was CNY 8,648,800.21, representing a 44.6% increase compared to CNY 5,968,446.88 in Q1 2020[52]. - Operating profit for the period was CNY 11,410,214.21, up from CNY 6,724,739.94 in the same period last year, indicating a growth of 69.9%[52]. - The company's gross profit margin improved, with operating profit for Q1 2021 at ¥23,634,014.51, up from ¥14,353,275.79 in the previous year, marking an increase of about 64.5%[47]. Cash Flow - The net cash flow from operating activities was ¥29,648,073.35, a significant improvement of 279.00% from -¥16,563,348.15 in the same period last year[8]. - Cash inflow from operating activities totaled CNY 132,773,791.63, compared to CNY 121,379,048.22 in the previous year, reflecting an increase of 9.8%[54]. - The cash outflow for operating activities was CNY 103,125,718.28, down from CNY 137,942,396.37 in the same period last year, indicating a decrease of 25.2%[55]. - The company's cash flow from investing activities increased by 452.56% year-on-year, due to the recovery of long-term equity investments and fixed assets[21]. - The cash flow from investing activities generated a net inflow of CNY 3,652,612.25, recovering from a net outflow of CNY 1,036,038.94 in the previous year[55]. - The net cash flow from investment activities was 3,551,067.09 CNY, a decrease of 49,078.99 CNY compared to the previous period[59]. - The company's cash and cash equivalents decreased from CNY 156,202,058.23 to CNY 132,140,402.93, a decline of about 15.4%[37]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,121,378,540.53, a decrease of 3.63% from ¥1,134,727,829.20 at the end of the previous year[8]. - Total liabilities decreased from CNY 418,068,165.87 to CNY 388,674,018.02, a reduction of approximately 7.0%[39]. - The company's short-term borrowings decreased significantly from CNY 102,876,698.53 to CNY 72,593,884.72, a reduction of approximately 29.4%[39]. - Current assets decreased from CNY 438,034,052.02 on December 31, 2020, to CNY 411,838,188.72 on March 31, 2021, representing a decline of approximately 6.0%[37]. - Total equity attributable to the parent company increased from CNY 730,267,783.85 to CNY 747,610,845.45, reflecting an increase of about 2.5%[40]. - The total liabilities of the company stood at ¥466,215,965.84, with total equity amounting to ¥849,247,516.65 as of the end of Q1 2021[46]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 33,644[12]. - The largest shareholder, Guangdong Zhiguang Biotechnology Co., Ltd., held 20.76% of the shares, amounting to 55,044,822 shares, with a portion of these shares frozen[12]. - The company’s controlling shareholder has 41,394,822 shares frozen, accounting for 15.61% of the total share capital, but this will not significantly impact the company's operations[24]. Strategic Focus and Operations - The company plans to deepen its focus on the regenerative medicine field and enhance its own product brand as part of its 2021-2025 strategic plan[23]. - The company reported a commitment to avoid engaging in any competitive activities with its subsidiaries, ensuring no direct or indirect competition with its products and services[28]. - The company has a strict adherence to its commitments regarding non-competition, with a promise to compensate for any losses incurred due to breaches of these commitments[29]. - The company is focused on maintaining its competitive edge by avoiding any potential conflicts of interest with its controlling shareholders[29]. - The company has committed to not utilizing its position to gain preferential treatment in business dealings, ensuring fair market practices[29]. Compliance and Governance - There were no violations of external guarantees during the reporting period, indicating a stable financial position[31]. - The company confirmed that there were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[32]. - The financial statements indicate a commitment to transparency and compliance with regulatory requirements, with no significant changes in net profit forecasted[30]. - The company has implemented measures to ensure fair and equitable treatment in any related party transactions, adhering to established decision-making processes[28]. Employee Compensation and Expenses - The company experienced a 64.18% decrease in employee compensation payable at the end of the reporting period compared to the end of the previous year, mainly due to the payment of 2020 annual bonuses[19]. - The company reduced its financial expenses by 50.61% year-on-year, primarily due to a decrease in loan scale and interest expenses[20]. - The company’s sales expenses rose by 58.8% year-on-year, reflecting increased marketing efforts following a period of reduced promotional activities due to the pandemic[20]. - Research and development expenses for Q1 2021 were ¥6,943,468.85, slightly down from ¥7,281,481.16 in Q1 2020, indicating a decrease of about 4.6%[46].